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Background: Colorectal cancer associated with Crohn’s disease (CD) is increasing in proportion to the number
of patients with CD in Japan. There are two subtypes of colorectal cancer with CD: sporadic cancer and
colitis-associated cancer. Early diagnosis of colitis-associated cancer is sometimes difficult; when colorectal cancer is
found in patients with CD, both colitis-associated cancer and sporadic cancer should be kept in mind. Here, we
describe a case of metachronous, colitis-associated rectal cancer that developed after the complete resection of an
adenoma that became a sporadic adenocarcinoma in a patient with longstanding CD. To the best of our knowledge,
this is the first report of colitis-associated cancer in a patient with CD after removal of a sporadic cancer.
Case presentation: We describe a 51-year old man with CD who had difficulty in defecation. A rectal polyp was
detected and a transanal resection of the polyp was performed. A histopathological examination showed an
adenoma with sporadic adenocarcinoma. After three years, a follow-up colonoscopy revealed a reddish, elevated
lesion in the patient’s rectum. A colonoscopic biopsy showed a signet ring cell carcinoma. We performed an
abdominoperineal resection of the rectum and a bilateral pelvic lymph node dissection. A histopathological
examination revealed a mucinous adenocarcinoma with signet ring cell carcinoma and lymph node metastasis. The
patient received adjuvant chemotherapy with oral uracil 224 mg combined with tegafur 100 mg plus leucovorin. No signs
of recurrence were noted at a follow-up 18 months after the third surgery and 60 months after the second surgery.
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Colorectal carcinoma (CRC) is a serious complication of
inflammatory bowel disease (IBD). CRC accounts for
approximately 15% of all deaths associated with IBD [1].
CRC has been thoroughly studied in conjunction with
ulcerative colitis (UC) [2], but CRC is not well under-
stood in conjunction with Crohn’s disease (CD). Several
reports have described an increased incidence of CRC in
CD [3-5]. However, relatively few studies have focused
on CRCs in CD. No well-defined risk factors have been
associated with the development of CRC in CD. Moreover,* Correspondence: tmizushima@gesurg.med.osaka-u.ac.jp
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reproduction in any medium, provided the orwe lack clear recommendations for surveillance and sur-
gical strategies for addressing CRC in CD [6]. CRC in
patients with IBD can be classified into two subtypes,
colitis-associated cancer and sporadic cancer, with differ-
ent pathogenic and clinicopathological characteristics [6].
Few reports have precisely described each type of CRC in
CD. To the best of our knowledge, no report has
described metachronous sporadic and colitis-associated
cancers in the same patient. This study is the first to
report colitis-associated adenocarcinoma in a patient with
CD after the removal of a sporadic adenocarcinoma.ral Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 2 Image of the surgical specimen shows the excised
rectal polyp, 4 cm in diameter.
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The patient was a 51-year old man with CD. He was ini-
tially diagnosed with CD at 23 years old. He had under-
gone ileocecal resection, owing to a stricture of the
terminal ileum, at 36 years old, and the residual small
intestine was 230 cm long. After the initial operation,
he was prescribed 5-aminosalicylic acid and home par-
enteral nutrition. He did not accept a recommended
colonoscopy examination, owing to anal pain.
In August 2008, the patient complained of difficulty in
defecation and consulted a physician at our hospital. A
colonoscopy examination showed a pedunculated rectal
polyp, 4 cm in diameter (Figure 1) and an anal stricture
due to proctitis. Histological examination of the biopsy
from the lesion showed an adenoma; no dysplasia was
detected around the polyp. A transanal resection of the
polyp was performed for treatment and final diagnosis
(Figure 2). The pathological findings revealed that the
polyp was an adenoma with well-differentiated adeno-
carcinoma without lymphatic or vascular invasion with
negative margin of cut end, and that no dysplasia or in-
flammation was present around the polyp; thus, the
polyp was diagnosed as a sporadic adenocarcinoma in
an adenoma, rather than a colitis-associated adenocar-
cinoma (Figure 3). Consistent with the results of the bi-
opsy, an endoscopic exploration showed no dysplasia in
the rectal mucosa, and immunohistochemistry showed
no p53-staining of the crypt base. These findings were
not consistent with colitis-associated CRC (Figure 4). In
July 2010, follow-up colonoscopy showed a longitudinal
ulcer scar from the descending colon to the ascending
colon and stenosis of the ileocolic anastomosis. We did
not find any apparent lesion in the rectum.
Three years after the second surgery, in August 2011,
colonoscopy examination revealed a reddish, elevatedFigure 1 Colonoscopic image shows a rectal polyp, 4 cm
in diameter.
Figure 3 Histopathological images. (A) The polyp was diagnosed
as sporadic adenocarcinoma in an adenoma, rather than
colitis-associated adenocarcinoma (×200, H & E). (B) Section of
tissue that bordered the polyp; there is no dysplasia or inflammation
(×100, H & E stain).
Figure 4 Immunohistochemical staining for p53 in rectal
mucosa tissue shows no dysplasia in the crypt base. These
findings were not consistent with a colitis-associated colorectal
cancer (×200).
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at a different site from the initial lesion. A colonoscopic
biopsy revealed a signet ring cell carcinoma. We per-
formed an abdominoperineal resection of the rectum
and a bilateral pelvic lymph node dissection (Figure 6).
Postoperative histological examination showed a mucin-
ous adenocarcinoma with signet ring cell carcinoma and
lymph node metastasis (Figure 7). Dysplasia was de-
tected in the rectal mucosa, and the crypt base was
immunohistochemically stained with p53. These findings
were consistent with colitis-associated CRC (Figure 8).
Postoperatively, the patient received adjuvant chemo-
therapy with 224 mg oral uracil combined with100 mg
tegafur plus leucovorin for 6 months. The patient has con-
tinued with regular follow-ups over the last 18 months
after the third surgery and over the last 60 months afterFigure 5 Colonoscopic image shows a reddish, elevated lesion
in the rectum. This was located in a site different site from the
initial lesion.the second surgery. He has also undergone regular exami-
nations. A regular colonoscopy examination was per-
formed every 6 months, and no relapse of colonic
inflammation or dysplasia was detected.
Discussion
CRC accounts for approximately 15% of all deaths in pa-
tients with IBD [6,7]. The risk of CRC for patients with
IBD increases by 0.5% to 1% yearly from 8 to 10 years
after the IBD diagnosis. A meta-analysis of published
studies that focused on the CRC risk in UC showed that
the risk of CRC for patients with colitis was 2% at
10 years, 8% at 20 years, and 18% after 30 years of colitis
[8]. Previously, CD was not considered a risk factor for
CRC; however, recent studies have shown that the CRC
risk in patients with colonic CD is similar to that of pa-
tients with UC [7,9].
In patients with IBD, CRC can take the form of sporadic
cancer or colitis-associated cancer. In patients with UC
who develop colitis-associated cancer, total proctocolect-
omy is the standard treatment; however, when sporadic
cancer occurs, total proctocolectomy is not always neces-
sary. In patients with CD, an indication for total proctoco-
lectomy has been controversial. However, it was also
reported that, when a diagnosis of colitis-associated can-
cer is known in advance of surgery, a total proctocolect-
omy should be seriously considered, to eliminate the risk
of metachronous disease. In 44% of these patients, dyspla-
sia occurred at a site remote from the site of the cancer
[10]. However, this patient had already undergone ileoce-
cal resection and the residual small intestine was 230 cm
long, resulting in intestinal failure syndrome requiring
home parental nutrition. For these reasons, we chose
abdominoperineal resection with colostomy, not total
proctocolectomy with ileostomy, in order to preserve the
colon and maintain absorption of water and electrolytes.
After the last surgery, we conducted intensive cancer sur-
veillance and neither a recurrence nor another lesion has
been detected at this time.
However, the site of inflammation should be resected,
owing to the risk of dysplasia. When the colon and rec-
tum are preserved in surgery, a scheduled, annual sur-
veillance with biopsies is strongly recommended [10]. It
is very important, when planning therapy and surveil-
lance after surgery, to perform a differential diagnosis to
distinguish between colitis-associated CRC and sporadic
CRC. However, it is often difficult to achieve this differ-
ential diagnosis in patients with IBD, particularly before
surgery [11,12].
The American Gastroenterological Association and
the British Society for Gastroenterology surveillance
guidelines have recommended beginning surveillance
after 8 to 10 years of disease in cases of CD or extensive
UC, and after 15 to 20 years of disease in cases of left-
Figure 6 Image of the surgical specimen shows a reddish and elevated lesion, 3cm in diameter.
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is based on is poor. It was reported that cancer has oc-
curred in a substantial number of patients with IBD
(17% to 28%) before the recommended time intervals for
surveillance [16].
Clinically, endoscopic examination is the most useful
screening method. However, even with endoscopic exam-
ination, it is often difficult to detect dysplastic changes.
Colitis-associated dysplasia may show subtle macroscopic
features that mimic a broad variety of lesions, ranging
from inflammation to carcinoma. Previous reports have
indicated that dysplastic lesions were not visible upon en-
doscopy in 50% to 80% of cases with colitis-associated
cancers [17]. Conversely, sporadic cancer mainly develops
from polyps that are on the pathway to becoming
adenoma-carcinomas, and a polyp is easily detectable,
even in a normal endoscopy examination. In contrast, the
gross appearance of colitis-associated neoplasms varies
from case to case, as the neoplasm develops from dyspla-
sia to become a carcinoma. Dysplastic lesions may be ir-
regularly delineated, plaque-like, irregularly elevated, or
verrucous structures; therefore, they are difficult to iden-
tify with normal endoscopy [18].
This case should make surgeons and endoscopists
aware of the possibility that patients with CD mayFigure 7 Histological image of a postoperative specimen shows
a mucinous adenocarcinoma with signet ring cell carcinoma.
(×200, H & E stain).develop either colitis-associated cancer or sporadic can-
cer. This report should alert surgeons and endoscopists
to look for colitis-associated cancers that are in a pre-
cancerous or early stage. In this case study, although we
performed annual colonoscopic surveillance, we did not
detect the second lesion, the colitis-associated cancer,
until it reached an advanced cancerous stage. Early de-
tection is highly important for avoiding surgeries, in-
cluding colectomy or proctectomy. However, it is often
difficult to detect colitis-associated cancers in dysplastic,
precancerous, or early stages. We need further investiga-
tion to discover novel biomarkers that make it possible
to detect cancer in blood samples or biopsies.
Conclusions
To the best of our knowledge, this is the first case report
of a metachronous colitis-associated rectal cancer that
arose in a patient with CD after removal of a sporadic
cancer. This case emphasized the importance for clini-
cians to bear in mind the possibilities of both sporadic
cancer and colitis-associated cancer when following-up
patients with CD. It is also important to consider
surgical therapy and surveillance after surgery, and to
perform a differential diagnosis to distinguish between
colitis-associated cancer and sporadic cancer. CRCFigure 8 Immunohistochemical staining for p53 in rectal
mucosa tissue shows dysplasia in the crypt base, consistent
with colitis-associated colorectal cancer. (×200).
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there is no defined surveillance strategy. However, pa-
tients with longstanding CD should receive cancer sur-
veillance as frequently as do patients with UC.
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